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Mouse double minute 2 (Mdm2) is a multifaceted oncoprotein that is highly 
regulated with distinct domains capable of cellular transformation.  Loss of Mdm2 
is embryonically lethal, making it difficult to study in a mouse model without 
additional genetic alterations.  Global overexpression through increased Mdm2 
gene copy number (Mdm2Tg) results in the development of hematopoietic 
neoplasms and sarcomas in adult animals.  In these mice, we found an increase 
in osteoblastogenesis, differentiation, and a high bone mass (HBM) phenotype.  
Since it was difficult to discern the cell lineage that generated this phenotype, we 
generated osteoblast-specific Mdm2 overexpressing (Mdm2TgOb) mice in two 
different strains, C57BL/6 and DBA.  These mice did not develop malignancies; 
however, these animals and the MG63 human osteosarcoma cell line with high 
levels of Mdm2 showed an increase in bone mineralization.  Importantly, 
overexpression of Mdm2 corrected aged-related bone loss in mice, providing a 








Bone is a complex and dynamic organ, simultaneously regulating 
hematopoiesis while continuously adapting to physiological conditions for optimal 
strength, support, and movement.  The bone remodeling process encompassing 
bone resorption and apposition reveals an intricate equilibrium regulated by 
osteoblasts (OBs) and osteoclasts (OCs).  Imbalances of remodeling can perturb 
bone microstructures and initiate pathologies such as bone loss, periodontal 
disease, arthritis, and malignancy.  
  The glycoprotein osteonectin is an important marker of OB differentiation, 
inducing mineralization in normal skeletal tissue [Doi et al., 1989; Romberg et al., 
1985; Romberg et al., 1986; Termine et al., 1981a; Termine et al., 1981b]; [Jundt 
et al., 1987; Termine et al., 1981b].  Consequently, osteonectin-null mice exhibit 
reduced OB and OC numbers with approximately 50% decrease in bone 
formation rate [Delany et al., 2000; Doi et al., 1989].   The osteonectin gene is 
regulated by numerous transcription factors including Sp1 in OBs [Chamboredon 
et al., 2003].  Sp1 is a zinc finger transcription factor that binds to GC rich motifs 
and cooperates with other transcription factors to induce gene expression [Mann 
et al., 2001].  Converse to SP1, the transcription factor and tumor suppressor 
p53 is an important regulator of OBs and OCs.  Loss of p53 (-/-) in OB precursors 
results in OB proliferation and OC differentiation, elevated levels of RUNX2, and 
generation of a high bone mass (HBM) phenotype [Liu and Li, 2010];[Wang et al., 
2006] . These mice also  develop of osteosarcoma as they age [Walkley et al., 
2008].  Furthermore, osteosarcoma cells with p53 deletion also exhibit high 
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levels of RUNX2 and enhanced osteogenesis compared to those with wild type 
p53 [He et al., 2015].   
Mdm2, a negative regulator of p53, has also been implicated in the 
development of osteosarcoma with gene amplification found in a third of high-
grade dedifferentiated osteosarcomas and the late stages of metastasis [Chen et 
al., 2012];[Guerin et al., 2016];[Yoshida et al., 2012];[Salinas-Souza et al., 2013].  
While the oncogenic function of Mdm2 is correlated with neoplastic development, 
little is known about the proto-oncogene role in maturing animals [Haines, 1997; 
Zhao et al., 2014].  Examination of Mdm2 expression patterns during 
embryogenesis shows ubiquitous expression during 7.5-11.5 days post coitum 
(dpc), and in the teeth at 14-18 dpc independent of p53 expression [Leveillard et 
al., 1998].  Deletion of Mdm2 in mice (Mdm2-/-) is embryonically lethal due to p53-
induced cell growth arrest or apoptosis, whereas Mdm2 -/-; p53-/- mice remain 
viable [Jones et al., 1995; Montes de Oca Luna et al., 1995]; [Maluszek, 2015; 
Manfredi, 2010].  Deletion of Mdm2 only in OB progenitor cells results in 
numerous skeletal defects and reduced mineralization leading to neonatal death 
[Lengner et al., 2006], suggesting that Mdm2 has both p53-dependent and 
independent roles.   
  
 The influence of Mdm2 upregulation in the rich cellular milieu remains 
largely unknown due to the inherent difficulties in investigating the function of 
Mdm2 in adult animals as p53-/-; Mdm2-/- animals develop hematopoietic 
malignancies and sarcomas early [Abbas et al., 2010; Chen et al., 2012; Das et 
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al., 2012; Lengner et al., 2006];[Jones et al., 1998; Pant et al., 2012].  Here we 
demonstrate that Mdm2 overexpression specific to osteoblast lineage cells leads 




Materials and Methods 
 
 
Global overexpressing Mdm2 (Mdm2Tg) C57BL/6 mice.  For these studies 3-
month-old male WT and globally overexpressing Mdm2Tg C57BL/6 mice were a 
generous gift from Stephen Jones [Jones et al., 1998].  Overexpression of Mdm2 
was analyzed by western blot analysis. 
 
Mdm2ObTg C57BL/6 and DBA mice.  For these studies, female and male WT 
and Mdm2ObTg (on a C57BL/6 or DBA background) were utilized.  DBA mice 
were obtained in-house.  There were no significant differences between male 
and female mice.  C57BL/6 mice were obtained from Jackson Laboratories. All 
procedures were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the Indiana University School of Medicine, and complied with NIH 
guidelines, and the Guide for the Care and Use of Laboratory Animals.  To 
generate Mdm2ObTg mice, the osteoblast and osteocyte specific promoter, 
collagen 1.7 (Col1.7) was ligated upstream of the Mdm2 cDNA and injected into 
embryos.  Overexpression of Mdm2 was monitored by western blot analysis. 
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BMD and μCT analysis of bone.  Whole body and femoral BMD (g/cm2) was 
measured in vivo by peripheral DEXA (PIXImus, GE Lunar Madison, WI).  
Trabecular bone parameters of the distal femur designated for histology were 
quantified by μCT (Skycan 1172) as previously described [Feher et al., 2010; 
Warden et al., 2008]; [Meijome et al., 2015; Weatherholt et al., 2013].  Images 
were binarized to calculate three-dimensional BV parameters: trabecular bone 
volume fraction (BV/TV, %), trabecular number (Tb.N, 1/mm), trabecular 
thickness (Tb.Th, mm), and trabecular separation (Tb.Sp, mm).   
 
Histology/histomorphometry.  WT and Mdm2ObTg mice were administered 
30mg/kg fluorochrome calcein (IP) 13 and 3 days prior to sacrifice to label 
actively forming bone surfaces.  Static and dynamic histomorphometric analysis 
of trabecular bone was performed on femurs as previously described [Feher et 
al., 2010; Meijome et al., 2015; Warden et al., 2008].  Histological measurements 
were made with a semiautomatic analysis system (Bioquant OSTEO 7.20.10, 
Bioquant Image Analysis Co.) attached to a microscope with an ultraviolet light 
source (Nikon Optiphot 2 microscope, Nikon).  Measurements were done on one 
stained (static) and one unstained (dynamic) section for each animal.   
 
Preparation of neonatal calvarial cells (OB).  Neonatal murine calvarial OB 
cells were prepared as previously described from WT and Mdm2ObTg C57BL/6 
and DBA mice [Horowitz et al., 1994].  Our technique is a modified version of the 
basic method described by Wong and Cohn [Wong and Cohn, 1975].  Dissected 
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calvaria from neonatal mice were treated with EDTA in PBS for 30 min and 
digested with collagenase (200U/mL) at 37°C.   Fractions 3-5 (20-35, 35-50, and 
50-65 min) were used as the OB starting population and seeded at 2 x104 
cells/ml (optimal pre-tested).  This population contains ~90% OB/OB precursors 
as previously established [Horowitz et al., 1994], [Simmons et al., 1982], [Jilka 
and Cohn, 1981].  OB cultures were fed twice per week with αMEM 
supplemented with 10% FBS, ascorbic acid (AA; 50 µg/ml added on day 0 and at 
all feedings), and β-glycerophosphate (BGP; 5mM added starting on day 7 and 
all subsequent feedings).  
 
In Vitro OC-like cell formation models. OC-like cells were generated as 
previously described [Kacena et al., 2004].  In brief, 2x106 control or Mdm2TgOb 
BM cells/ml and 20,000 primary calvarial OB/ml were grown in a α-MEM 
supplemented with 10% FCS and 10-8 M 1,25(OH)2D3.  The media was changed 
every other day for 6-8 days for OC formation then fixed with 2.5% 
gluteraldehyde in PBS for 30 min at RT.  TRAP positive multinucleated cells (>3 
nuclei) were quantified. 
 
Cell culture.  Human MG63 osteosarcoma cells were maintained in 10% FBS 
DMEM, and treated with ascorbic acid (AA; 1ul/ml) and ß-glycerolphosphate 
(BGP; 10ul/ml) to induce differentiation.  
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Protein analysis. Cell monolayers were harvested by scraping with in ice-cold 
1X PBS.  After centrifugation PBS was removed, pelleted cells were lysed with 
urea lysis buffer on ice for >2 hr and debris centrifuged. Supernatant was 
collected and protein concentrations were determined by BioRad assay.  Protein 
was fractionated by SDS/PAGE and transferred to PVDF membrane (Amersham 
Biosciences).  Membranes were blocked for 1 hr at room temperature (RT) in 5% 
non-fat dry milk in PBST, and subsequently incubated with primary antibodies in 
milk (1:1000) for 2 hr at RT.  Mdm2 (SMP14, 2A10, and 4B11), Osteonectin 
(AON-1), and GAPDH (6C5) were purchased from Millipore (Calbiochem, 
Billerica, MA). β-actin (C4) was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).  
 
Cell cycle analysis.  WT and Mdm2ObTg OB were assessed on days 1, 3, 5, and 
7 of culture.  Cells were stained with equal volumes of staining buffered 
(0.1mg/ml propidium iodide + 0.6% Nonidet P40 in PBS) and 2mg/ml RNase as 
described previously [Srour et al., 1992].  OB were mixed well and incubated on 
ice for 30 min.  A FACS caliber flow cytometer (BDIS) was used to determine the 
percentage of cells in phase G0/G1 and S/G2+M. 
 
Quantitative analysis of calcium deposition by alizarin red staining.  To 
evaluate calcium deposition, monolayers of neonatal calvarial OB were stained 
with Alizarin Red S after 14 days in culture as previously described [Stanford et 
al., 1995].  Briefly, monolayers were washed 2X with PBS, subsequently fixed in 
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ice cold 70% (v/v) ethanol for 1 hr, and washed 2X with water.  Monolayers were 
stained with 40mM Alizarin Red S (pH 4.2) for 10 min at RT while shaking.  




Statistical analysis.  Data are presented as the Mean ±1 SEM unless otherwise 
stated.  Experiments were performed as duplicates or triplicates at least 3X.  The 
sample size for in vivo studies is presented in the corresponding figure legends.  
Student’s t-test was performed when only two groups were compared.  For ease 
of reporting and to increase sample size, data from both genders which shared 
identical properties were combined for all the in vivo data analysis.  One-way 
analyses of variances (one-way ANOVA) with LSD were used to make multiple 
group comparisons. 
 
 Two-way analyses of variances (two-way ANOVA) were used to 
determine significant main effect contribution in cell co-culture groups, with BM 
genotype and OB genotype being the independent variables, as well as 
significant interaction effect between these independent variables.  Statistical 
Package for Social Sciences (IBM SPSS 19; SPSS Inc., Armonk, NY) software 




Previous efforts to understand Mdm2 function on oncogenic 
transformation through generation of global overexpressing transgenic mice 
(Mdm2Tg) led to lymphoma and sarcoma phenotypes in adult mice [Jones et al., 
1998].  While this limited the utility of the model for studying physiological roles of 
Mdm2 in aged animals, the effects of global Mdm2 over-expression on 
osteogenesis, bone volume and architecture could be examined prior to 4 
months of age.  Micro-computed tomographic (μCT) analysis of 3-month-old 
male Mdm2Tg mice revealed an increase in trabecular bone fraction (BV/TV; 
Figure 1a,and c ) and improved architecture in the vertebrae (Figure d-f).  
Additionally, the material bone mineral density (mBMD) of Mdm2Tg mice were 
significantly greater than in wild-type (WT) (Figure 1b).  Overexpression of Mdm2 
also significantly enhanced ex vivo OB differentiation from BM stromal cells 
(BMSCs) represented by mineralized nodules and increased alkaline 
phosphatase positive colonies compared to WT (Figure 1g, h).  
Though not definitive, these findings from the global Mdm2Tg strongly 
suggested a direct role of Mdm2 in differentiation and function.  To definitively 
determine this skeletal phenotype was due to a direct role of Mdm2 in OBs, 
rather than indirect role via its effects in other cells in the BM microenvironment, 
we generated mice that overexpress Mdm2 only in cells of the osteogenic 
lineage (Mdm2TgOb) using a construct that contained the collagen 1.7kb fragment 
of the Col1a1 promoter (Col1.7) upstream of the murine Mdm2 cDNA.  This 
promoter activity is limited to maturing OBs, and osteocytes.  Two founder lines 
were generated that contained the Mdm2 transgene (Mdm2TgOb) as detected by 
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PCR.  To confirm that this promoter was active during OB differentiation, BMSCs 
were isolated from long bones and vertebrae.  These cells were treated with 
ascorbic acid and β-glycerophosphate to induce osteoblastogenesis.  Western 
blot analysis showed that Mdm2 levels were higher in BMSCs isolated from 
Mdm2TgOb long bone and vertebrae compared to controls (Figure 2a). 
Histological analysis of Mdm2 distal femur demonstrated Mdm2 staining in OBs 
and not OCs (Figure 2b). Mdm2TgOb OB cell proliferation was also higher than 
controls (Figure 2c).  This result is consistent with the increase in calvarial OB 
proliferation observed in OB generated from p53-/-; Rb-/- mice as compared to WT 
counterparts.  Lysates from Mdm2TgOb calvaria OBs show marked reductions in 
p53 levels compared to control OBs.  Interestingly, p53-/- mice have a significant 
increase in BMD, BFR, and OB number [Wang et al., 2006].  Additionally, 
Mdm2TgOb OBs exhibited a 2-fold increase in osteocalcin mRNA compared to 
controls (Figure 2d).    
Alizarin red staining of calcium deposition showed enhanced 
mineralization in Mdm2TgOb compared to WT OB cultures (Figure 3d top panel).  
We also overexpressed or knocked down Mdm2 expression in p53-null MG63 
human osteosarcoma cells (Mdm2-MG63 and shMdm2-MG63, respectively).   
Western blot analysis confirms transduction as levels of Mdm2 were increased in 
Mdm2-MG63 cells and decreased in ShMdm2-MG63 cells (Figure 3a).   Western 
blot analysis revealed increased levels of osteonectin (a marker of osteoblast 
differentiation) in mouse Mdm2TgOb and Mdm2-MG63 cells compared to controls 
(Figure 3b top and bottom panels), while shMdm2-MG63 cells had a lower level 
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of osteonectin compared to control cells (Figure 3b bottom panel).  Western blot 
analysis shows that in shMdm2 MG63 cells, Sp1 levels are diminished compared 
to pLKO empty vector controls (Figure 3c top panel), and elevated in Mdm2-
MG63 compared to pLV empty vector controls (Figure 3c bottom panel).  We 
found that Mdm2-overexpressing cells were more effective at mineralization 
compared to control cells (Figure 3d middle panel).  Conversely, shRNA-
mediated knockdown of endogenous Mdm2 in MG63 cells inhibited 
mineralization compared to control MG63 cells (Figure 3d bottom panel).  The 
data from both mouse and human cells implicate that Mdm2 may be regulating 
mineralization downstream of Sp1 through osteonectin.   
Given that we observed a direct effect of Mdm2 expression on OB 
mineralization in vitro in human and murine cells, we next analyzed control and 
Mdm2TgOb mice for changes in their bone phenotype.  Dual-energy X-ray 
absorptiometry (DEXA) showed that Mdm2TgOb mice had marked increases in 
their whole body and femoral bone mineral density (BMD) compared to controls 
(Figure 4a).  In Figures 4b-h, μCT and histological analyses revealed increases 
in bone volume fraction (BV/TV) and mineral apposition rate, but no differences 
in trabecular thickness, trabecular separation, or bone formation rate.  Calcein 
labeled cross sections from the femoral midshaft (Figure 5a) revealed a 
significant increase in cortical bone area (Figure 5b), cross sectional area (Figure 
5c), endocortical surface area (Figure 5d) and endosteal bone formation rate 
(Figure 5f) with a concomitant decrease in endocortical area (Figure 5e) 
compared to controls.   
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Interestingly, in vivo histological analysis revealed significant increases in 
osteoclast (OC) number on periosteal surfaces of the femur in Mdm2TgOb as 
compared to those generated from controls (Figure 5g).  BM cells were isolated 
from femurs of Mdm2TgOb and controls, cultured in the presence of MCSF and 
RANKL (to promote osteoclast differentiation) and co-cultured with OB (control 
and Mdm2tgob), and OCs were enumerated as tartrate-resistant acid phosphatase 
(TRAP) positive cells with >3 nuclei.  There was approximately a 2-fold increase 
in OCs generated from Mdm2TgOb cultures as compared to those generated from 
controls (Figure 5 h).   
Next, to more directly compare our findings with that observed in the 
global Mdm2Tg mice, we examined the vertebrae of Mdm2TgOb mice.  In Figure 
6a-e, vertebrae from Mdm2TgOb mice, like Mdm2Tg mice, have significant 
increases in BV/TV and trabecular number, with decreases in trabecular 
separation.  Analysis of both the vertebral and whole body BMD in Mdm2TgOb 
mice was also significantly elevated compared to controls.  The vertebral data is 
from 9-month-old female mice, an age when control mice already begin to lose 
bone mass. Interestingly, in the 9-month-old Mdm2TgOb mice the age-related 
osteoporosis was corrected compared to littermate controls of the same age 
(Figure 6a).  
  
Discussion 
While the globally Mdm2 overexpressing transgenic animals developed 
tumors arising from soft tissue or hematopoietic system, we followed the 
 14 
Mdm2TgOb animals for over a year and there was no evidence of neoplastic 
development.  The major difference between the global Mdm2Tg and osteoblast-
specific Mdm2TgOb is sustained expression versus acute expression.  The acute 
expression of Mdm2TgOb may be necessary for the generation of high quality 
bone as observed in our study versus sustained expression, which leads to 
neoplastic development.  
Many studies have been conducted on mdm2-/- and conditional knockout 
animals; however, these studies are limited as a lethal phenotype is evident early 
during development due to p53.  Knockout of p53 and Mdm2 lead to 
developmental defects or neoplastic development.  Counter to using a knockout 
approach, Mdm2Tg animal, we were able to gain insight into physiological activity 
of Mdm2 in the presence of p53 in older animals.  OB differentiation is guided by 
several extracellular signaling factors including fibroblast growth factors, 
parathyroid hormone, estrogen, bone morphogenetic protein, transforming 
growth factor β, Wnt, and members of the growth hormone/IGF family 
[Erlebacher et al., 1998; Hu et al., 2005; Isogai et al., 1996; Marie, 2003; Okazaki 
et al., 2002; Yamaguchi et al., 2000; Zheng et al., 1992].  All or most of these 
factors can have an  influence on Mdm2 gene expression or protein levels and 
activity [Araki et al., 2010; Heron-Milhavet and LeRoith, 2002; Shaulian et al., 
1997; Yang et al., 2006].   
 Our data shows a high bone mass phenotype (Fig.1). The increase in 
bone mass and bone mass turnover of these animals guided us to investigate 
what induces this phenotype downstream.  We show that increased Mdm2 is 
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associated with increased osteonectin, a factor important for mineralization.  This 
was evident in our animal model and more importantly, in human cells  in vitro 
(Fig 3).  Upon examination of the transcription factor implicated in the induction of 
osteonectin, Sp1, we found it was elevated in human and murine models (Fig 3).  
The link to Mdm2 is important as osteonectin knockout animals present with 
severe skeletal defects [Boskey et al., 2003; Delany et al., 2000].  Thus, the 
biometric and molecular data support a novel physiological role for Mdm2 in the 
regulation of the bone microenvironment.   
Collectively, our data suggest that Mdm2 has a significant proto-oncogene 
function in bone formation. Thus, diminished levels of Mdm2 may be involved in 
human bone pathologies.  Moreover, targeting Mdm2 for acute expression may 
be an effective method to alleviate age-associated osteoporosis.  
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Figure 1. Global overexpression of Mdm2 causes a high bone volume phenotype 
and increases osteogenic differentiation.  A. µCT imaging of Mdm2Tg vertebrae 
compared to wild type control. B. MDM2 overexpression increases mBMD of trabecular 
bone. C.-F. Mdm2 improves bone architecture with increases in BV/TV, Tb.N, decrease 
in Tb.Sp, and corresponding increase in Tb.Th.  G. MDM2 overexpression enhances OB 
differentiation from BMSCs quantitated by mineralized nodules. H. Mdm2 
overexpression increases Alkaline phosphatase colonies. Asterisk signifies statistical 
significance at p<0.05. 
 
 
Figure 2. Conditional overexpression of Mdm2 in osteogenic cells promotes 
osteogenic differentiation.  A. Representative Western blotting showing OB-specific 
overexpression of Mdm2 in bone marrow from Mdm2TgOb compared to wild type 
littermate controls upon induction of OB differentiation.  Bone marrow cells were isolated 
from both the long bones (LB) and vertebrae (V) of 6-week-old female littermates.  
Mdm2 expression is higher in bone marrow cultures derived from Tg females as 
compared to cultures derived from WT control females.  B. Mdm2 staining in OBs (red 
arrow) and not in OCs (black arrow) C. An increase in osteoblast proliferation from 
calvarial OB isolated from Mdm2TgOb is observed compared to wild type littermate control 
mice.  D.  An increase in osteocalcin mRNA in Mdm2TgOb mice compare to WT controls.  
Asterisk signifies statistical significance at p<0.05.  
 
 
Figure 3. Conditional overexpression of Mdm2 in osteogenic cells increases 
osteonectin, Sp1, and mineralization. A. (Top panel) Western Blot analysis 
demonstrating elevated Mdm2 levels in human MG63 cells compared to wild type 
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controls and (Bottom panel) decreased Mdm2 levels in silenced Mdm2 MG63 cells 
compared to vector control. B. (Top panel) Western blot analysis demonstrate elevated 
levels of osteonectin in mouse cells with overexpression of Mdm2 protein levels 
compared to vector control and (Bottom panel) elevated levels of osteonectin with 
increasing Mdm2 levels. C. (Top panel) Elevated Sp1 protein levels in pLKO vector 
control MG63 cells compared to ShMdm2 MG63 cells.  (Bottom panel) Elevated Sp1 
protein levels in Mdm2 overexpressed MG63 cells compared to pLV vector control. D. 
Mineralization by Alizarin Red staining.  (Top panel) Mouse calvarial OB Mdm2TgOb 
shows increased mineralization compared to wild type OB control.  (Middle panel) 
Overexpression of Mdm2 in MG63 human osteosarcoma cells resulted in greater 
mineralization compared to empty pLV vector control.  (Bottom panel) Silencing of 
Mdm2 (ShMdm2) in MG63 human osteosarcoma cells resulted in significantly less 
mineralization compared to empty pLKO vector control. Asterisk signifies statistical 
significance at p<0.05. 
 
 
Figure 4. Conditional overexpression of Mdm2 in osteogenic cells increases bone 
mass. A. DEXA was used to evaluate whole body and femoral BMD of Mdm2TgOB mice 
compared to WT littermate controls. B. µCT and C. Histological staining (Von Kossa) of 
femurs at 6 weeks and 6 months. D. Trabecular Bone Volume Fraction or BV/TV. E. 
Trabecular Thickness. F. Trabecular Separation. G. Mineral Apposition Rate. H. Bone 




Figure 5. Conditional overexpression of Mdm2 in osteogenic cells increases 
cortical bone mass and formation. A. (Left panel) Calcein labeled, femoral midshaft, 
cross-sections from wild type controls and Mdm2TgOb mice and (Right panel) at 6 weeks 
and 6 months. B. Bone area. C. Cross-sectional area. D. Endocortical surface area. E. 
Endocortical area. F. Histomorphometry shows an increase in endosteal bone formation 
rate (BFR) of Mdm2TgOb compared to wild type controls. G. Femoral TRAP staining 
(black arrows) and quantitation demonstrating increased osteoclastogenesis in 
Mdm2TgOb mice. H. In vitro TRAP staining and quantitation using wild type osteoblast 
progenitors and co-cultured with wild type or Mdm2tgob increased osteoclast (left) or 
Mdm2tgob osteoblast progenitors cells with bone marrow cells from wild type or Mdm2tgob 
(right).  Asterisk signifies statistical significance at p<0.05. 
 
 
Figure 6. Osteoblast-conditioned overexpression of Mdm2 increases the density 
and trabecular bone volume in the vertebra of adult mice. A. µCT images of 
vertebrae from 6-week and 9-11-month-old mice display marked differences in bone 
phenotype between wild type controls and Mdm2TgOb mice. B. Vertebral BV/TV. C. 
Vertebral Tb.N. D. Vertebral trabecular separation. E. DEXA measurements evaluating 
vertebral and whole body BMD demonstrate increases in BMD of Mdm2TgOb mice 
compared to wild type littermate controls.  Data in all figures is presented as the average 
± SEM.  Asterisk signifies statistical significance at p<0.05. 
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